Reply to Hodges et al. Comment on "Kura et al. Cost-Effectiveness Analysis of Clesrovimab for Respiratory Syncytial Virus in Infants in the United States. Vaccines 2026, 14, 411".

IF 3.5 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2026-08-31 DOI:10.3390/vaccines14090759

Klodeta Kura, John C Lang, Dawei Wang, Yoonyoung Choi, Michelle G Goveia, Anushua Sinha, Yao-Hsuan Chen, Elamin H Elbasha

引用次数: 0

Abstract

We thank the authors for their interest in our analysis [...].

查看原文本刊更多论文

回复Hodges等人。评论“Kura et al.”在美国，克列罗维单抗治疗婴儿呼吸道合胞病毒的成本-效果分析。疫苗2026,14,411”。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.